
Opinion|Videos|April 7, 2025
18-Month Retrospective Claims Analysis Study Information on Ruxolitinib
Author(s)Gary M. Owens, MD , Lawrence Eichenfield, MD
Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare utilization, and concomitant medication use compared to conventional therapies, while maintaining a consistent safety profile across diverse patient populations and disease severities.
Advertisement
Episodes in this series

Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
Medicaid tech companies pledge $600 million to help states update systems
4
Why the great pharma-MedTech divide is healthcare’s biggest miss
5






















